Porous silicon nanocarriers for dual targeting tumor associated endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers

Cancer Letters

Volumn 334, Issue 2, 2013, Pages 319-327

  Yokoi, Kenji ^a,b   Godin, Biana ^a   Oborn, Carol J ^b   Alexander, Jenolyn F ^a   Liu, Xuewu ^a   Fidler, Isaiah J ^b   Ferrari, Mauro ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Endothelial cells; Ly6C; Marker; Nanocarriers; Porous silicon

Indexed keywords

ANTIBODY; CD59 ANTIGEN; LY6C ANTIBODY; NANOCARRIER; SILICON; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BIOACCUMULATION; CELL INFILTRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; MACROPHAGE; MOUSE; NONHUMAN; PANCREAS CANCER; POROSITY; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; STROMA CELL; SURFACE PROPERTY; TARGET CELL;

ANIMALS; ANTIGENS, CD59; ANTIGENS, LY; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; FEMALE; HUMANS; MACROPHAGES; MALE; MICE; MICE, NUDE; NANOSTRUCTURES; PANCREATIC NEOPLASMS; SILICON;

MUS MUSCULUS;

EID: 84878257355     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.09.001     Document Type: Article

References (64)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Pliarchopoulou K., Pectasides D. Pancreatic cancer: current and future treatment strategies. Cancer Treat. Rev. 2009, 35:431-436.
3. NCI, Pancreatic cancer, 2012. <> (last accessed 02.05.12). http://www.cancer.gov/cancertopics/types/pancreatic.
4. Parsons C.M., Sutcliffe J.L., Bold R.J. Preoperative evaluation of pancreatic adenocarcinoma. J. Hepatobiliary Pancreat. Surg. 2008, 15:429-435.
5. Kim M.P., Gallick G.E. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin. Cancer Res. 2008, 14:1284-1285.
6. Vaccaro V., Melisi D., Bria E., Cuppone F., Ciuffreda L., Pino M.S., Gelibter A., Tortora G., Cognetti F., Milella M. Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin. Ther. Targets 2011, 15:1183-1196.
7. Mahadevan D., Von Hoff D.D. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol. Cancer Ther. 2007, 6:1186-1197.
8. Mueller M.M., Fusenig N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4:839-849.
9. Maeda H., Matsumura Y. EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy. Adv. Drug Deliv. Rev. 2011, 63:129-130.
10. Torchilin V.P. Passive and active drug targeting: drug delivery to tumors as an example. Handb. Exp. Pharmacol. 2010, 3-53.
11. Khan J.A., Kudgus R.A., Szabolcs A., Dutta S., Wang E., Cao S., Curran G.L., Shah V., Curley S., Mukhopadhyay D., Robertson J.D., Bhattacharya R., Mukherjee P. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. PLoS ONE 2011, 6:e20347.
12. Weissleder R., Kelly K., Sun E.Y., Shtatland T., Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotech. 2005, 23:1418-1423.
13. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 2010, 188:759-768.
14. Ahmed F., Steele J.C., Herbert J.M., Steven N.M., Bicknell R. Tumor stroma as a target in cancer. Curr. Cancer Drug Targets 2008, 8:447-453.
15. Philbrick W.M., Palfree R.G., Maher S.E., Bridgett M.M., Sirlin S., Bothwell A.L. The CD59 antigen is a structural homologue of murine Ly-6 antigens but lacks interferon inducibility. Eur. J. Immunol. 1990, 20:87-92.
16. Seifert P.S., Roth I., Schmiedt W., Oelert H., Okada N., Okada H., Bhakdi S. CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesions. Atherosclerosis 1992, 96:135-145.
17. van Beijnum J.R., Dings R.P., van der Linden E., Zwaans B.M., Ramaekers F.C., Mayo K.H., Griffioen A.W. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006, 108:2339-2348.
18. Godin B., Tasciotti E., Liu X., Serda R.E., Ferrari M. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc. Chem. Res. 2011.
19. Bruns C.J., Harbison M.T., Kuniyasu H., Eue I., Fidler I.J. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999, 1:50-62.
20. Yokoi K., Hawke D., Oborn C.J., Jang J.Y., Nishioka Y., Fan D., Kim S.W., Kim S.J., Fidler I.J. Identification and validation of SRC and phospho-SRC family proteins in circulating mononuclear cells as novel biomarkers for pancreatic cancer. Transl. Oncol. 2011, 4:83-91.
21. Yokoi K., Sasaki T., Bucana C.D., Fan D., Baker C.H., Kitadai Y., Kuwai T., Abbruzzese J.L., Fidler I.J. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res. 2005, 65:10371-10380.
22. Langley R.R., Ramirez K.M., Tsan R.Z., Van Arsdall M., Nilsson M.B., Fidler I.J. Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res. 2003, 63:2971-2976.
23. Nagendra S., Schlueter A.J. Absence of cross-reactivity between murine Ly-6C and Ly-6G. Cytometry A 2004, 58:195-200.
24. Chiappini C., Tasciotti E., Fakhoury J.R., Fine D., Pullan L., Wang Y.C., Fu L., Liu X., Ferrari M. Tailored porous silicon microparticles: fabrication and properties. Chemphyschem. 2010, 11:1029-1035.
25. Tasciotti E., Liu X., Bhavane R., Plant K., Leonard A.D., Price B.K., Cheng M.M., Decuzzi P., Tour J.M., Robertson F., Ferrari M. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol. 2008, 3:151-157.
26. Godin B., Gu J., Serda R.E., Bhavane R., Tasciotti E., Chiappini C., Liu X., Tanaka T., Decuzzi P., Ferrari M. Tailoring the Degradation Kinetics of Mesoporous Silicon Structures through PEGylation. J. Biomed Mater. Res. A 2010, 94:1236-1243.
27. Tasciotti E., Godin B., Martinez J.O., Chiappini C., Bhavane R., Liu X., Ferrari M. Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles. Mol. Imag. 2011, 10:56-68.
28. Liang M., Liu X., Cheng D., Liu G., Dou S., Wang Y., Rusckowski M., Hnatowich D.J. Multimodality nuclear and fluorescence tumor imaging in mice using a streptavidin nanoparticle. Bioconjug. Chem. 2010, 21:1385-1388.
29. Xia B., Xiao S.-J., Guo D.-J., Wang J., Chao J., Liu H.-B., Pei J., Chen Y.-Q., Tang Y.-C., Liu J.-N. Biofunctionalisation of porous silicon (PS) surfaces by using homobifunctional cross-linkers. J. Mater. Chem. 2006, 16:570-578.
30. Tanaka T., Godin B., Bhavane R., Nieves-Alicea R., Gu J., Liu X., Chiappini C., Fakhoury J.R., Amra S., Ewing A., Li Q., Fidler I.J., Ferrari M. In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. Int. J. Pharm. 2010, 402:190-197.
31. Garber K. Stromal depletion goes on trial in pancreatic cancer. J. Nat. Cancer Inst. 2010, 102:448-450.
32. Neesse A., Michl P., Frese K.K., Feig C., Cook N., Jacobetz M.A., Lolkema M.P., Buchholz M., Olive K.P., Gress T.M., Tuveson D.A. Stromal biology and therapy in pancreatic cancer. Gut 2011, 60:861-868.
33. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., Frese K.K., DeNicola G., Feig C., Combs C., Winter S.P., Ireland-Zecchini H., Reichelt S., Howat W.J., Chang A., Dhara M., Wang L., Rückert F., Grützmann R., Pilarsky C., Izeradjene K., Hingorani S.R., Huang P., Davies S.E., Plunkett W., Egorin M., Hruban R.H., Whitebread N., McGovern K., Adams J., Iacobuzio-Donahue C., Griffiths J., Tuveson D.A. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science, New York, NY 2009, 324:1457-1461.
34. Jain R.K. Barriers to drug delivery in solid tumors. Sci. Am. 1994, 271:58-65.
35. Jain R.K. Transport of molecules, particles, and cells in solid tumors. Ann. Rev. Biomed. Eng. 1999, 1:241-263.
36. Langley R.R., Fidler I.J. The seed and soil hypothesis revisited - the role of tumor-stroma interactions in metastasis to different organs. Int. J. Cancer 2011, 128:2527-2535.
37. Erkan M., Reiser-Erkan C., Michalski C.W., Kleeff J. Tumor microenvironment and progression of pancreatic cancer. Exp. Oncol. 2010, 32:128-131.
38. Chu G.C., Kimmelman A.C., Hezel A.F., DePinho R.A. Stromal biology of pancreatic cancer. J. Cell Biochem. 2007, 101:887-907.
39. Kolev M., Towner L., Donev R. Complement in cancer and cancer immunotherapy. Arch. Immunol. Ther. Exp. (Warsz) 2011, 59:407-419.
40. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631.
41. Kim S.J., Kim J.S., Papadopoulos J., Wook Kim S., Maya M., Zhang F., He J., Fan D., Langley R., Fidler I.J. Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis. Am. J. Pathol. 2009, 174:1972-1980.
42. Kuwana M., Okazaki Y., Kodama H., Satoh T., Kawakami Y., Ikeda Y. Endothelial differentiation potential of human monocyte-derived multipotential cells. Stem Cells 2006, 24:2733-2743.
43. Canham L.T. INSPEC (Information Service), Properties of Porous Silicon 1987, INSPEC, London.
44. Decuzzi P., Ferrari M. The receptor-mediated endocytosis of nonspherical particles. Biophys. J. 2008, 94:3790-3797.
45. Decuzzi P., Lee S., Bhushan B., Ferrari M. A theoretical model for the margination of particles within blood vessels. Ann. Biomed. Eng. 2005, 33:179-190.
46. Godin B., Driessen W.H., Proneth B., Lee S.Y., Srinivasan S., Rumbaut R., Arap W., Pasqualini R., Ferrari M., Decuzzi P. An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. Adv. Genet. 2010, 69:31-64.
47. Mann A.P., Tanaka T., Somasunderam A., Liu X., Gorenstein D.G., Ferrari M. E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv. Mater. 2011, 23:H278-H282.
48. Tanaka T., Mangala L.S., Vivas-Mejia P.E., Nieves-Alicea R., Mann A.P., Mora E., Han H.D., Shahzad M.M., Liu X., Bhavane R., et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010, 70:3687-3696.
49. Shen H., You J., Zhang G., Ziemys A., Li Q., Bai L., Deng X., Erm D.R., Liu X., Li C., Ferrari M. Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv. Health Mater. 2012, 1:84-89.
50. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
51. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
52. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., Rimoldi M., Biswas S.K., Allavena P., Mantovani A. Macrophage polarization in tumour progression. Semin. Cancer Biol. 2008, 18:349-355.
53. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010, 7:653-664.
54. Danhier F., Feron O., Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148:135-146.
55. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007, 9:E128-147.
56. Godin B., Chiappini C., Srinivasan S., Alexander J.F., Yokoi K., Ferrari M., Decuzzi P., Liu X. Discoidal porous silicon particles: fabrication and biodistribution in breast cancer bearing mice. Adv. Funct. Mater. 2012.
57. Serda R.E., Mack A., van de Ven A.L., Ferrati S., Dunner K., Godin B., Chiappini C., Landry M., Brousseau L., Liu X., et al. Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small 2010, 6:2691-2700.
58. Kong R., Sun B., Jiang H., Pan S., Chen H., Wang S., Krissansen G.W., Sun X. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett. 2010, 291:90-98.
59. Yokoi K., Fidler I.J. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin. Cancer Res. 2004, 10:2299-2306.
60. Glazer E.S., Zhu C., Massey K.L., Thompson C.S., Kaluarachchi W.D., Hamir A.N., Curley S.A. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin. Cancer Res. 2010, 16:5712-5721.
61. Bardhan R., Lal S., Joshi A., Halas N.J. Theranostic nanoshells: from probe design to imaging and treatment of cancer. Acc. Chem. Res. 2011, 44:936-946.
62. Savill J., Dransfield I., Gregory C., Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat. Rev. Immunol. 2002, 2:965-975.
63. Movahedi K., Laoui D., Gysemans C., Baeten M., Stange G., Van den Bossche J., Mack M., Pipeleers D., In't Veld P., De Baetselier P., Van Ginderachter J.A. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010, 70:5728-5739.
64. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New Engl. J. Med. 1986, 315:1650-1659.